01093.HK
CSPC Pharmaceutical Group Limited
HKSE · Healthcare · Drug Manufacturers - General · CN
HKD 9.69
+0.78%Jul 27, 2026, 12:59 UTC
CSPC Pharmaceutical Group announced that its Class 1 innovative drug Amoxetine Hydrochloride Enteric-coated Tablets (HA1406) met the primary endpoint in a Phase III clinical trial for depression.
Source:Jul 27, 2026, 02:09 UTC
CSPC Pharmaceutical Group's self-developed second-generation long-acting antipsychotic injection, Paliperidone Palmitate Injection, received marketing approval from China's National Medical Products Administration for the treatment of acute and maintenance phases of schizophrenia.
Source:Jul 24, 2026, 02:05 UTC
CSPC Pharmaceutical Group's new drug application for Enwei Trastuzumab Injection has been accepted by China's National Medical Products Administration.
Source:Jul 23, 2026, 02:09 UTC
Takeda's neuroscience drug Ozeyue (Opreton) received approval from China's National Medical Products Administration for treating narcolepsy type 1 in patients aged 16 and above, making China the first market globally to approve the drug.
Jul 21, 2026, 19:36 UTC
Several Chinese public funds, including E Fund, China Asset Management, Fullgoal Fund, and China Universal Fund, increased their holdings in Hong Kong-listed biotech stocks, triggering the 5% disclosure threshold for Baioct-B, 3SBio, CSPC Pharmaceutical Group, Kelun-Biotech, and H&H International Holdings.
← PreviousPage 2